Statins in nervous system-associated diseases: Angels or devils?

Pharmazie

Volumn 69, Issue 6, 2014, Pages 448-454

  Lei, Q ^a   Peng, W N ^a   You, H ^a   Hu, Z P ^a   Lu, W ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADVERSE OUTCOME; ALZHEIMER DISEASE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; BRAIN TUMOR; CEREBROVASCULAR DISEASE; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DEPRESSION; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; MULTIPLE SCLEROSIS; MYOPATHY; NEUROLOGIC DISEASE; NEUROLOGIST; NIGHTMARE; PARKINSON DISEASE; PERIPHERAL NEUROPATHY; PLEIOTROPY; REVIEW; SLEEP DISORDER; SUBARACHNOID HEMORRHAGE;

ANIMALS; BRAIN NEOPLASMS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NERVOUS SYSTEM DISEASES; NEURODEGENERATIVE DISEASES;

EID: 84903301576     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2014.3892     Document Type: Review

References (106)

1. 4S (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389.
2. Amarenco P, Bogousslavsky J, Callahan A, 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA, Stroke Prevention by Aggressive Reduction in Cholesterol (1995) Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies Collaboration. Lancet 346: 1647-1653.
3. Cholesterol Levels I (2006) High-dose atorvastatin after stroke or transient ischemic attack. New Engl J Med 355: 549-559.
4. Amarenco P, Labreuche J, Lavallee P, Touboul PJ (2004) Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 35: 2902-2909. (Pubitemid 39565192)
5. Arboix A, Garcia-Eroles L, Oliveres M, Targa C, Balcells M, Massons J (2010) Pretreatment with statins improves early outcome in patients with first-ever ischaemic stroke: a pleiotropic effect of statins or a beneficial effect of hypercholesterolemia? BMC Neurol 10: 47.
6. Ariesen MJ, Claus SP, Rinkel GJ, Algra A (2003) Risk factors for intracerebral hemorrhage in the general population: a systematic review. Stroke 34: 2060-2065. (Pubitemid 36944806)
7. Asahi M, Huang Z, Thomas S, Yoshimura S, Sumii T, Mori T, Qiu J, Amin-Hanjani S, Huang PL, Liao JK, Lo EH, MoskowitzMA(2005) Protective effects of statins involving both eNOS and tPA in focal cerebral ischemia. J Cerebral Blood Flow Metabolism 25: 722-729. (Pubitemid 40705607)
8. Ayer RE, Ostrowski RP, Sugawara T, Ma Q, Jafarian N, Tang J, Zhang JH (2013) Statin-induced T-lymphocyte modulation and neuroprotection following experimental subarachnoid hemorrhage. Acta Neurochir Suppl 115: 259-266.
9. Backes JM, Howard PA (2003) Association of HMG-CoA reductase inhibitors with neuropathy. Ann Pharmacother 37: 274-278. (Pubitemid 36172871)
10. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R, Cholesterol Treatment Trialists C (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366: 1267-1278.
11. Baker SK, Vladutiu GD, Peltier WL, Isackson PJ, Tarnopolsky MA (2008) Metabolic myopathies discovered during investigations of statin myopathy. Canadian J Neurol Sci 35: 94-97. (Pubitemid 351518296)
12. Bang OY, Saver JL, Liebeskind DS, Starkman S, Villablanca P, Salamon N, Buck B, Ali L, Restrepo L, Vinuela F, Duckwiler G, Jahan R, Razinia T, Ovbiagele B (2007) Cholesterol level and symptomatic hemorrhagic transformation after ischemic stroke thrombolysis. Neurology 68: 737-742. (Pubitemid 46667898)
13. Biffi A, Devan WJ, Anderson CD, Cortellini L, Furie KL, Rosand J, Rost NS (2011) Statin treatment and functional outcome after ischemic stroke: case-control and meta-analysis. Stroke 42: 1314-1319.
14. Blanco M, Nombela F, Castellanos M, Rodriguez-Yanez M, Garcia-Gil M, Leira R, Lizasoain I, Serena J, Vivancos J, Moro MA, Davalos A, Castillo J (2007) Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology 69: 904-910. (Pubitemid 47329591)
15. Boudreau DM, Yu O, Johnson J (2010) Statin use and cancer risk: a comprehensive review. Expert Opin Drug Safety 9: 603-621.
16. Cakmak A, Yemisci M, Koksoy C, Yazgan U, Dincer D, Dalkara T (2007) Statin pre-treatment protects brain against focal cerebral ischemia in diabetic mice. J Surg Res 138: 254-258. (Pubitemid 46365720)
17. Cartwright MS, Jeffery DR, Nuss GR, DonofrioPD(2004) Statin-associated exacerbation of myasthenia gravis. Neurology 63: 2188. (Pubitemid 39636283)
18. Chan YM, Merkens LS, Connor WE, Roullet JB, Penfield JA, Jordan JM, Steiner RD, Jones PJ (2009) Effects of dietary cholesterol and simvastatin on cholesterol synthesis in Smith-Lemli-Opitz syndrome. Pediat Res 65: 681-685.
19. Collins R, Armitage J, Parish S, Sleight P, Peto R, Heart Protection Study Collaborative G (2004) Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 363: 757-767.
20. Colman E, Szarfman A, Wyeth J, Mosholder A, Jillapalli D, Levine J, Avigan M (2008) An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA's spontaneous adverse event reporting system. Pharmacoepidemiol Drug Safety 17: 1068-1076.
21. Cui JJ, Wang D, Gao F, Li YR (2012) Effects of atorvastatin on pathological changes in brain tissue and plasma MMP-9 in rats with intracerebral hemorrhage. Cell Biochem Biophys 62: 87-90.
22. de Lau LM, Stricker BH, Breteler MM (2007) Serum cholesterol, use of lipid-lowering drugs, and risk of Parkinson disease. Mov Disord 22: 1985. (Pubitemid 350134222)
23. Dhar R, Diringer M (2012) Statins and anti-inflammatory therapies for subarachnoid hemorrhage. Curr Treat Opt Neurol 14: 164-174.
24. Di Legge S, Koch G, Diomedi M, Stanzione P, Sallustio F (2012) Stroke prevention: managing modifiable risk factors. Stroke Res Treat 2102: 391538.
25. Dufouil C, Richard F, Fievet N, Dartigues JF, Ritchie K, Tzourio C, Amouyel P, Alperovitch A (2005) APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study. Neurology 64: 1531-1538. (Pubitemid 40617688)
26. Edwards IR, Star K, Kiuru A (2007) Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosis-like syndrome: an analysis of individual case safety reports from vigibase. Drug Safety 30: 515-525. (Pubitemid 46873076)
27. Edwards PA, Ericsson J (1998) Signaling molecules derived from the cholesterol biosynthetic pathway: mechanisms of action and possible roles in human disease. Curr Opin Lipidol 9: 433-440. (Pubitemid 28495552)
28. Ehrenberg BL, Lamon-Fava S, Corbett KE, McNamara JR, Dallal GE, Schaefer EJ (1999) Comparison of the effects of pravastatin and lovastatin on sleep disturbance in hypercholesterolemic subjects. Sleep 22: 117-121. (Pubitemid 29097906)
29. Elkind MS (2006) Statins as acute-stroke treatment. Int J Stroke 1: 224-225.
30. Elkind MS, Flint AC, Sciacca RR, Sacco RL (2005) Lipid-lowering agent use at ischemic stroke onset is associated with decreased mortality. Neurology 65: 253-258. (Pubitemid 41022370)
31. Fantini J, Carlus D, Yahi N (2011) The fusogenic tilted peptide (67-78) of alpha-synuclein is a cholesterol binding domain. Biochim Biophys Acta 1808: 2343-2351.
32. Gaist D, Andersen L, Hallas J, Toft Sorensen H, Schroder HD, Friis S (2013) Use of statins and risk of glioma: a nationwide case-control study in Denmark. Brit J Cancer 108: 715-720.
33. Gao X, Simon KC, Schwarzschild MA, Ascherio A(2012) Prospective study of statin use and risk of Parkinson disease. Arch Neurol 69: 380-384.
34. Garg K, Sinha S, Kale SS, Chandra PS, Suri A, Singh MM, Kumar R, Sharma MS, Pandey RM, Sharma BS, Mahapatra AK (2013) Role of simvastatin in prevention of vasospasm and improving functional outcome after aneurysmal sub-arachnoid hemorrhage: a prospective, randomized, double-blind, placebo-controlled pilot trial. Brit J Neurosurg 27: 181-186.
35. Grable-Esposito P, Katzberg HD, Greenberg SA, Srinivasan J, Katz J, Amato AA (2010) Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve 41: 185-190.
36. Gregoor PJ (2006) Atorvastatin may cause nightmares. BMJ 332: 950.
37. Group SC, Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R (2008) SLCO1B1 variants and statin-induced myopathy-a genomewide study. New Engl J Med 359: 789-799.
38. Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM (2009) Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry 80: 13-17.
39. Halcox JP, Deanfield JE (2004) Beyond the laboratory: clinical implications for statin pleiotropy. Circulation 109: II42-48. (Pubitemid 38724155)
40. Heart Protection Study Collaborative G (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360: 7-22.
41. Henchcliffe C, Beal MF (2008) Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nature Clin Pract Neurol 4: 600-609.
42. Hu G, Antikainen R, Jousilahti P, Kivipelto M, Tuomilehto J (2008) Total cholesterol and the risk of Parkinson disease. Neurology 70: 1972-1979.
43. Jira PE, Wevers RA, de Jong J, Rubio-Gozalbo E, Janssen-Zijlstra FS, van Heyst AF, Sengers RC, Smeitink JA (2000) Simvastatin. A new therapeutic approach for Smith-Lemli-Opitz syndrome. J Lipid Res 41: 1339-1346. (Pubitemid 30666899)
44. Johnson-Anuna LN, Eckert GP, Franke C, Igbavboa U, Muller WE, Wood WG (2007) Simvastatin protects neurons from cytotoxicity by upregulating Bcl-2 mRNA and protein. J Neurochem 101: 77-86. (Pubitemid 46426484)
45. Kagan A, Popper JS, Rhoads GG (1980) Factors related to stroke incidence in Hawaii Japanese men. The Honolulu Heart Study. Stroke 11: 14-21. (Pubitemid 10160370)
46. Kamboh MI, Ferrell RE, DeKosky ST (1998) Genetic association studies between Alzheimer's disease and two polymorphisms in the low density lipoprotein receptor-related protein gene. Neuroscience Lett 244: 65-68. (Pubitemid 28157392)
47. Karasinska JM, Hayden MR (2011) Cholesterol metabolism in Huntington disease. Nature Rev Neurol 7: 561-572.
48. Kim BJ, Lee SH, Ryu WS, Kang BS, Kim CK,Yoon BW(2009) Lowlevel of low-density lipoprotein cholesterol increases hemorrhagic transformation in large artery atherothrombosis but not in cardioembolism. Stroke 40: 1627-1632.
49. King DS, Wilburn AJ, Wofford MR, Harrell TK, Lindley BJ, Jones DW (2003) Cognitive impairment associated with atorvastatin and simvastatin. Pharmacotherapy 23: 1663-1667. (Pubitemid 37485319)
50. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, Iivonen S, Mannermaa A, Tuomilehto J, Nissinen A, Soininen H(2002) Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Int Med 137: 149-155. (Pubitemid 34827510)
51. Kotti TJ, Ramirez DM, Pfeiffer BE, Huber KM, Russell DW (2006) Brain cholesterol turnover required for geranylgeraniol production and learning in mice. Proc Nat Acad Sci USA 103: 3869-3874. (Pubitemid 43376647)
52. Koyuturk M, Ersoz M, Altiok N (2004) Simvastatin induces proliferation inhibition and apoptosis in C6 glioma cells via c-jun N-terminal kinase. Neurosci Lett 370: 212-217. (Pubitemid 39370881)
53. Kumar A, Sharma N, Mishra J, Kalonia H(2013) Synergistical neuroprotection of rofecoxib and statins against malonic acid induced Huntington's disease like symptoms and related cognitive dysfunction in rats. Eur J Pharmacol 709: 1-12.
54. Lee YC, Lin CH, Wu RM, Lin MS, Lin JW, Chang CH, Lai MS (2013) Discontinuation of statin therapy associates with Parkinson disease: a population-based study. Neurology 81: 410-416.
55. Li G, Larson EB, Sonnen JA, Shofer JB, Petrie EC, Schantz A, Peskind ER, Raskind MA, Breitner JC, Montine TJ (2007) Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology 69: 878-885. (Pubitemid 47329587)
56. Liberopoulos EN, Mikhailidis DP (2006) Could statins be useful in the treatment of patients with migraine? Headache 46: 672-675.
57. LIPID (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. New Engl J Med 339: 1349-1357.
58. Lo YL, Leoh TH, Loh LM, Tan CE (2003) Statin therapy and small fibre neuropathy: a serial electrophysiological study. J Neurol Sci 208: 105-108. (Pubitemid 36294161)
59. Marwarha G, Rhen T, Schommer T, Ghribi O (2011) The oxysterol 27-hydroxycholesterol regulates alpha-synuclein and tyrosine hydroxylase expression levels in human neuroblastoma cells through modulation of liverXreceptors and estrogen receptors-relevance to Parkinson's disease. J Neurochem 119: 1119-1136.
60. McKinney JS, Kostis WJ (2012) Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials. Stroke 43: 2149-2156.
61. Merlo L, Cimino F, Scibilia A, Ricciardi E, Chirafisi J, Speciale A, Angileri FF, Raffa G, Priola S, Saija A, Germano A (2011) Simvastatin administration ameliorates neurobehavioral consequences of subarachnoid hemorrhage in the rat. J Neurotrauma 28: 2493-2501.
62. Minino AM, Murphy SL, Xu J, Kochanek KD (2011) Deaths: final data for 2008. National vital statistics reports: from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System 59: 1-126.
63. Mitchel YB, Kramer MS, Matzura-Wolfe DM, Strittmatter W, Peskind E, Ferris S, Galasko D, Sano M, Marin D, Clark C (1995) The effect of simvastatin on cerebrospinal fluid levels of apolipoprotein E in patients with Alzheimer's disease. Atherosclerosis 115: S113.(Supp 1).
64. Mosshammer D, Lorenz G, Meznaric S, Schwarz J, Muche R, Morike K (2009) Statin use and its association with musculoskeletal symptoms-a cross-sectional study in primary care settings. Family Pract 26: 88-95.
65. Muldoon MF, Manuck SB, Mendelsohn AB, Kaplan JR, Belle SH (2001) Cholesterol reduction and non-illness mortality: meta-analysis of randomised clinical trials. BMJ 322: 11-15. (Pubitemid 32066249)
66. Neuvonen PJ, Niemi M, Backman JT (2006) Drug interactions with lipidlowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 80: 565-581. (Pubitemid 44908269)
67. Ni Chroinin D, Callaly EL, Duggan J, Merwick A, Hannon N, Sheehan O, Marnane M, HorganG, Williams EB, Harris D, Kyne L, McCormack PM, Moroney J, Grant T, Williams D, Daly L, Kelly PJ (2011) Association between acute statin therapy, survival, and improved functional outcome after ischemic stroke: the North Dublin Population Stroke Study. Stroke 42: 1021-1029.
68. Nichols GA, Koro CE (2007) Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients. Clinical Ther 29: 1761-1770. (Pubitemid 47494553)
69. Okopien B, Krysiak R, Madej A, Belowski D, Zielinski M, Kowalski J, Herman ZS (2004) Effect of simvastatin and fluvastatin on plasma fibrinogen levels in patients with primary hypercholesterolemia. Pol J Pharmacol 56: 781-787. (Pubitemid 40287480)
70. Otruba P, Kanovsky P, Hlustik P (2011)Treatment with statins and peripheral neuropathy: results of 36-months a prospective clinical and neurophysiological follow-up. Neuroendocrinol Lett 32: 688-690.
71. Ovbiagele B, Saver JL, Bang H, Chambless LE, Nassief A, Minuk J, Toole JF, Crouse JR, Investigators VS (2006) Statin treatment and adherence to national cholesterol guidelines after ischemic stroke. Neurology 66: 1164-1170. (Pubitemid 43739697)
72. Parra A, Kreiter KT, Williams S, Sciacca R, Mack WJ, Naidech AM, Commichau CS, Fitzsimmons BF, Janjua N, Mayer SA, Connolly ES, Jr. (2005) Effect of prior statin use on functional outcome and delayed vasospasm after acute aneurysmal subarachnoid hemorrhage: a matched controlled cohort study. Neurosurgery 56: 476-484; discussion 476-484.
73. Patassini S, Giampa C, Martorana A, Bernardi G, Fusco FR (2008) Effects of simvastatin on neuroprotection and modulation of Bcl-2 and BAX in the rat quinolinic acid model of Huntington's disease. Neurosci Lett 448: 166-169.
74. Patterson MC, Di Bisceglie AM, Higgins JJ, Abel RB, Schiffmann R, Parker CC, Argoff CE, Grewal RP, Yu K, Pentchev PG, et al. (1993) The effect of cholesterol-lowering agents on hepatic and plasma cholesterol in Niemann-Pick disease type C. Neurology 43: 61-64. (Pubitemid 23035358)
75. Paul F,Waiczies S,Wuerfel J, Bellmann-Strobl J, Dorr J,Waiczies H, Haertle M, Wernecke KD, Volk HD, Aktas O, Zipp F (2008) Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis. PloS one 3: e1928.
76. Phillips PS, Haas RH, Bannykh S, Hathaway S, Gray NL, Kimura BJ, Vladutiu GD, England JD, Scripps Mercy Clinical Research C (2002) Statin-associated myopathy with normal creatine kinase levels. Ann Int Med 137: 581-585.
77. Prasanna P, Thibault A, Liu L, Samid D (1996) Lipid metabolism as a target for brain cancer therapy: synergistic activity of lovastatin and sodium phenylacetate against human glioma cells. J Neurochem 66: 710-716. (Pubitemid 26036701)
78. Reid PC, Lin S, Vanier MT, Ohno-Iwashita Y, Harwood HJ, Jr., Hickey WF, Chang CC, Chang TY (2008) Partial blockage of sterol biosynthesis with a squalene synthase inhibitor in early postnatal Niemann-Pick type C npcnih null mice brains reduces neuronal cholesterol accumulation, abrogates astrogliosis, but may inhibit myelin maturation. J Neurosci Meth 168: 15-25.
79. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, de Simone G, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Greenlund KJ, Hailpern SM, Heit JA, Ho PM, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, McDermott MM, Meigs JB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Rosamond WD, Sorlie PD, Stafford RS, Turan TN, Turner MB, Wong ND, Wylie-Rosett J, American Heart Association Statistics C, Stroke Statistics S (2011) Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 123: e18-e209.
80. Sadeghi MM, Tiglio A, Sadigh K, O'Donnell L, Collinge M, Pardi R, Bender JR (2001) Inhibition of interferon-gamma-mediated microvascular endothelial cell major histocompatibility complex class II gene activation by HMG-CoA reductase inhibitors. Transplantation 71: 1262-1268. (Pubitemid 32507145)
81. Scott RS, Lintott CJ, Wilson MJ (1991) Simvastatin and side effects. New Zealand Med J 104: 493-495.
82. Shepardson NE, Shankar GM, Selkoe DJ (2011) Cholesterol level and statin use in Alzheimer disease: I. Review of epidemiological and preclinical studies. Arch Neurol 68: 1239-1244.
83. SilvaM, Matthews ML, Jarvis C, Nolan NM, Belliveau P, Malloy M, Gandhi P (2007) Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin Ther 29: 253-260. (Pubitemid 46661859)
84. Sing CF, Davignon J (1985) Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am J Hum Genet 37: 268-285. (Pubitemid 15053161)
85. Sironi L, Cimino M, Guerrini U, Calvio AM, Lodetti B, Asdente M, Balduini W, Paoletti R, Tremoli E (2003) Treatment with statins after induction of focal ischemia in rats reduces the extent of brain damage. Arterioscler Thromb Vasc Biol 23: 322-327. (Pubitemid 36231947)
86. Soma MR, Baetta R, De Renzis MR, Mazzini G, Davegna C, Magrassi L, Butti G, Pezzotta S, Paoletti R, Fumagalli R (1995) In vivo enhanced antitumor activity of carmustine [N,N'-bis(2-chloroethyl)-N-nitrosourea] by simvastatin. Cancer Res 55: 597-602.
87. Stuart SA, Robertson JD, Marrion NV, Robinson ES (2013) Chronic pravastatin but not atorvastatin treatment impairs cognitive function in two rodent models of learning and memory. PloS one 8: e75467.
88. Stuve O, Youssef S, Steinman L, Zamvil SS (2003) Statins as potential therapeutic agents in neuroinflammatory disorders. Curr Opin Neurol 16: 393-401. (Pubitemid 36688309)
89. Tapia-Perez JH, Rupa R, Zilke R, Gehring S,Voellger B, Schneider T (2013) Continued statin therapy could improve the outcome after spontaneous intracerebral hemorrhage. Neurosurg Rev 36: 279-287; discussion 287.
90. Tierney EF, Thurman DJ, Beckles GL, Cadwell BL (2013) Association of statin use with peripheral neuropathy in the U.S. population 40 years of age or older. J Diabetes 5: 207-215.
91. Vaughan CJ, Gotto AM, Jr., Basson CT (2000) The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 35: 1-10. (Pubitemid 30061252)
92. Vergouwen MD, de Haan RJ, Vermeulen M, Roos YB (2008) Statin treatment and the occurrence of hemorrhagic stroke in patients with a history of cerebrovascular disease. Stroke 39: 497-502. (Pubitemid 351619482)
93. Vevera J, Fisar Z, Kvasnicka T, Zdenek H, Starkova L, Ceska R, Papezova H (2005) Cholesterol-lowering therapy evokes time-limited changes in serotonergic transmission. Psychiatry Res 133: 197-203. (Pubitemid 40312153)
94. Vollmer T, Key L, Durkalski V, Tyor W, Corboy J, Markovic-Plese S, Preiningerova J, Rizzo M, Singh I (2004) Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363: 1607-1608. (Pubitemid 38625664)
95. Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM (2003) Statinassociated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy 23: 871-880. (Pubitemid 36875671)
96. Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K (2005) Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 64: 277-281.
97. Wierzbicki AS, Lumb PJ, Semra Y, Chik G, Christ ER, Crook MA (1999) Atorvastatin compared with simvastatin-based therapies in the management of severe familial hyperlipidaemias. QJM 92: 387-394. (Pubitemid 29346883)
98. Willey JZ, Elkind MS (2010) 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of central nervous system diseases. Arch Neurol 67: 1062-1067.
99. Yang D, Han Y, Zhang J, Chopp M, Seyfried DM (2012) Statins enhance expression of growth factors and activate the PI3K/Akt-mediated signaling pathway after experimental intracerebral hemorrhage. World J Neurosci 2: 74-80.
100. Yang D, Zhang J, Han Y, James E, Chopp M, Seyfried DM (2013) Acute statin treatment improves recovery after experimental intracerebral hemorrhage. World J Neurosci 3: 69-75.
101. Yoshimura Y, Murakami Y, Saitoh M, Yokoi T, Aoki T, Miura K, Ueshima H, Nozaki K, Group SSSR (2014) Statin use and risk of cerebral aneurysm rupture: a hospital-based case-control study in Japan. J Stroke Cerebrovasc Dis, in press.
102. You H, Lu W, Zhao S., Hu Z, Zhang J (2013) The relationship between statins and depression: a review of the literature. Exp Opin Pharmacother 14: 1467-1476.
103. Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, Bravo M, Mitchell DJ, Sobel RA, Steinman L, Zamvil SS (2002) The HMGCoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420: 78-84. (Pubitemid 35291443)
104. Zacco A, Togo J, Spence K, Ellis A, Lloyd D, Furlong S, Piser T (2003) 3-hydroxy-3-methylglutaryl coenzymeAreductase inhibitors protect cortical neurons from excitotoxicity. J Neurosci 23: 11104-11111. (Pubitemid 37548945)
105. Zhang X, Tao Y, Wang J, Garcia-Mata R, Markovic-Plese S (2013) Simvastatin inhibits secretion of Th17-polarizing cytokines and antigen presentation by DCs in patients with relapsing remitting multiple sclerosis. Eur J Immunol 43: 281-289.
106. Zheng Z, Sheng L, Shang H (2013) Statins and amyotrophic lateral sclerosis: a systematic review and meta-analysis. Amyotroph Lateral Scler Frontotemporal Degener 14: 241-245.